Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX USA.
Joint Department of Biomedical Engineering University of North Carolina and North Carolina State University Chapel Hill NC USA.
J Am Heart Assoc. 2023 Jul 4;12(13):e027851. doi: 10.1161/JAHA.122.027851. Epub 2023 Jun 29.
Background Prevention strategies targeting standard modifiable cardiovascular risk factors (SMuRFs; diabetes, hypertension, smoking, hypercholesterolemia) are critical to improving cardiovascular disease outcomes. However, acute myocardial infarction (AMI) among individuals who lack 1 or more SMuRFs is not uncommon. Moreover, the clinical characteristics and prognosis of SMuRFless individuals are not well characterized. Methods and Results We analyzed AMI hospitalizations from 2000 to 2014 captured by the ARIC (Atherosclerosis Risk in Community) study community surveillance. AMI was classified by physician review using a validated algorithm. Clinical data, medications, and procedures were abstracted from the medical record. Main study outcomes included short- and long-term mortality within 28 days and 1 year of AMI hospitalization. Between 2000 and 2014, a total of 742 (3.6%) of 20 569 patients with AMI were identified with no documented SMuRFs. Patients without SMuRFs were less likely to receive aspirin, nonaspirin antiplatelet therapy, or beta blockers and less often underwent angiography and revascularization. Compared with those with one or more SMuRFs, patients without SMuRFs had significantly higher 28-day (odds ratio, 3.23 [95% CI, 1.78-5.88]) and 1-year (hazard ratio, 2.09 [95% CI, 1.29-3.37]) adjusted mortality. When examined across 5-year intervals from 2000 to 2014, the incidence of 28-day mortality significantly increased for patients without SMuRFs (7% to 15% to 27%), whereas it declined for those with 1 or more SMuRFs (7% to 5% to 5%). Conclusions Individuals without SMuRFs presenting with AMI have an increased risk of all-cause mortality with an overall lower prescription rate for guideline-directed medical therapy. These findings highlight the need for evidence-based pharmacotherapy during hospitalization and the need to discover new markers and mechanisms for early risk identification in this population.
针对标准可改变心血管风险因素(SMuRFs;糖尿病、高血压、吸烟、高胆固醇血症)的预防策略对于改善心血管疾病结局至关重要。然而,在缺乏 1 种或多种 SMuRFs 的个体中发生急性心肌梗死(AMI)并不少见。此外,SMuRF 缺乏个体的临床特征和预后尚不清楚。
我们分析了 2000 年至 2014 年 ARIC(社区动脉粥样硬化风险)研究社区监测中记录的 AMI 住院患者。AMI 由经过验证的算法进行医师审查进行分类。从病历中提取临床数据、药物和程序。主要研究结果包括 AMI 住院后 28 天和 1 年的短期和长期死亡率。在 2000 年至 2014 年期间,在 20569 例 AMI 患者中共有 742 例(3.6%)被确定为无记录的 SMuRFs。无 SMuRFs 的患者不太可能接受阿司匹林、非阿司匹林抗血小板治疗或β受体阻滞剂,并且不太经常接受血管造影和血运重建。与有 1 种或多种 SMuRFs 的患者相比,无 SMuRFs 的患者在 28 天(比值比,3.23 [95%置信区间,1.78-5.88])和 1 年(风险比,2.09 [95%置信区间,1.29-3.37])时的调整死亡率显著更高。当在 2000 年至 2014 年的 5 年间隔内进行检查时,无 SMuRFs 患者的 28 天死亡率显著增加(7%至 15%至 27%),而有 1 种或多种 SMuRFs 的患者则下降(7%至 5%至 5%)。
出现 AMI 的无 SMuRFs 个体的全因死亡率风险增加,而指南指导的药物治疗的总体处方率较低。这些发现突出表明需要在住院期间进行基于证据的药物治疗,并需要在该人群中发现新的标志物和机制以进行早期风险识别。